Nutriband (NTRB) AI Stock Analysis

• Market Cap: $90.79M
• Dividend Yield: N/A
• Average Volume (3M): 132.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: 18.92%
• EPS Growth: -17.30%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.98
• Shares Outstanding: 11,154,171
• 10 Day Avg. Volume: 236,733
• 30 Day Avg. Volume: 132,401
• PEG Ratio: 0.14
• Price to Book (P/B): 3.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.07
• Enterprise Value/Market Cap: 0.32
• Enterprise Value/Revenue: 3.48
• Enterprise Value/Gross Profit: 36.87
• Enterprise Value/Ebitda: -0.87
• 1Y Price Target: $11.75
• Price Target Upside: 43.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 60 Neutral
• Price Target: $9.00 ▲(9.76%Upside)

Nutriband's overall stock score is driven by a strong technical analysis indicating positive momentum and a strategic partnership enhancing brand visibility. However, financial performance challenges and valuation concerns due to negative earnings limit the score.

Positive Factors

Market Potential

The additional safety from the abuse-deterrent technology could potentially grow the market and drive upward revisions to estimates.

Product Development

The AVERSA Fentanyl patch could prevent abuse and accidental misuse of fentanyl transdermal patches.

Negative Factors

Regulatory Challenges

Analysts believe the Phase 1 clinical trial will show sufficient abuse deterrence for Nutriband to file a New Drug Application using the 505(b)(2) pathway for approval.

Nutriband Business Overview & Revenue Model

Company Description

Nutriband Inc. (NTRB) is a pharmaceutical and healthcare company specializing in the development of transdermal and topical therapeutic products. The company operates primarily in the pharmaceutical sector, focusing on the creation and commercialization of advanced drug delivery systems that provide safer and more effective ways of administering medication. Nutriband’s core products include transdermal patches designed to deliver medication through the skin, offering an alternative to traditional oral or injectable delivery methods.

How the Company Makes Money

Nutriband makes money through the development, manufacture, and sale of its transdermal delivery products. The company generates revenue by selling its pharmaceutical delivery systems to healthcare providers, pharmaceutical companies, and distributors. Key revenue streams include the sale of its proprietary transdermal patches, licensing agreements for its drug delivery technology, and partnerships with other pharmaceutical companies to develop and commercialize new transdermal products. Additionally, Nutriband may receive milestone payments and royalties from partnerships and licensing deals, contributing to its earnings.

Nutriband Financial Statement Overview

Summary

Nutriband exhibits slow revenue growth with significant challenges in profitability and cash flow. The balance sheet is stable with low leverage, but persistent losses and reliance on external financing are critical concerns.

Income Statement

Nutriband has shown modest revenue growth over the years, but profitability remains a challenge with consistently negative EBIT and net income margins. Revenue increased by 2.6% from 2024 to 2025, indicating slow growth. However, the gross profit margin has been volatile, and the net profit margin remains deeply negative, reflecting the company's difficulty in managing costs in relation to revenues.

Balance Sheet

The balance sheet is relatively stable, with a low debt-to-equity ratio indicating conservative leverage. Stockholders' equity remains strong at approximately 86% of total assets. However, the company's return on equity is negative due to ongoing net losses, which could be concerning for long-term sustainability.

Cash Flow

Nutriband's cash flow situation is challenging, with negative operating and free cash flows reflecting ongoing operational losses. The operating cash flow to net income ratio is negative, indicating cash outflows exceed net losses. The company relies heavily on financing cash flows to offset operating cash deficits, which is not sustainable long-term.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.40M	2.14M	2.09M	2.08M	1.42M	943.70K
Gross Profit	788.61K	699.30K	862.11K	750.41K	504.31K	361.32K
EBITDA	-9.68M	-10.18M	-5.12M	-4.11M	-5.74M	-2.48M
Net Income	-9.97M	-10.48M	-5.49M	-4.81M	-8.42M	-3.21M
Balance Sheet
Total Assets	6.15M	7.47M	7.52M	9.46M	12.74M	9.93M
Cash, Cash Equivalents and Short-Term Investments	2.96M	4.31M	492.94K	1.99M	4.89M	151.99K
Total Debt	282.44K	186.35K	241.28K	185.81K	134.57K	1.79M
Total Liabilities	1.05M	1.04M	1.08M	883.39K	880.38K	2.82M
Stockholders Equity	5.10M	6.43M	6.44M	8.57M	11.86M	7.11M
Cash Flow
Free Cash Flow	-5.22M	-4.72M	-3.58M	-3.07M	-2.89M	-297.06K
Operating Cash Flow	-5.13M	-4.63M	-3.53M	-2.99M	-2.81M	-297.06K
Investing Cash Flow	-91.17K	-92.04K	-51.76K	-79.30K	-81.59K	66.99K
Financing Cash Flow	-162.86K	8.54M	2.09M	160.07K	7.63M	371.87K

Nutriband Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTRB, the sentiment is Positive. The current price of 8.2 is above the 20-day moving average (MA) of 8.09, above the 50-day MA of 7.05, and above the 200-day MA of 6.15, indicating a bullish trend. The MACD of 0.44 indicates Positive momentum. The RSI at 52.85 is Neutral, neither overbought nor oversold. The STOCH value of 14.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTRB.

Nutriband Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTRB	60 Neutral	$90.79M	―	-108.02%	―	18.92%	-17.30%
AVTX	52 Neutral	$53.60M	―	678.24%	―	-69.59%	―
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%
SER	44 Neutral	$52.63M	―	45.59%	―	34.04%	55.34%
CBUS	44 Neutral	$79.16M	―	-157.73%	―	104.78%	40.41%
ANRO	42 Neutral	$69.85M	―	-38.04%	―	―	―

Nutriband Corporate Events

Nutriband Partners with Charlotte FC for Brand Visibility

On April 4, 2025, Nutriband Inc. announced an Associate Partnership agreement with Charlotte FC to enhance brand visibility for its products, including AI Tape, which is manufactured in the Charlotte area. This partnership aims to promote Nutriband’s platform technology AVERSA, potentially the world’s first abuse deterrent patch platform for chronic pain management, thereby strengthening its market presence and stakeholder engagement.